RNS Number:0651T
Antisoma PLC
10 December 2003


Result of Annual General Meeting


10 December 2003, London, UK: Antisoma plc (LSE: ASM), the biopharmaceutical
company specialising in novel anti-cancer drugs, today announces that all
resolutions at yesterday's Annual General Meeting were passed.

Proxy votes relating to the resolutions set out in the AGM Notice can be viewed
at www.antisoma.com

Enquiries:
     Antisoma plc

     Raymond Spencer,                          Tel: +44 (0)20 8799 8200
     Chief Financial  Officer

     Financial Dynamics
     Ben Atwell                                Tel: +44 (0)20 7831 3113


About Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel
products for the treatment of cancer. The Company fills its development pipeline
by acquiring promising new product candidates from internationally recognised
academic or cancer research institutions.  Its core activity is the preclinical
and clinical development of these drug candidates. Antisoma forms partnerships
with pharmaceutical companies to bring its products to market.  In November
2002, Antisoma formed a broad strategic alliance with Roche to develop and
commercialise products from Antisoma's pipeline. Please visit www.antisoma.com
for further information about Antisoma.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RAGDKLFBXLBXFBL